Arbutus Biopharma Investor Presentation
Arbutus Biopharma Corporation has posted an updated corporate presentation for Q4 2026 to its website and filed it with the SEC. The presentation outlines the company's strategic focus on developing a functional cure for chronic hepatitis B virus (HBV), including the clinical development of its lead candidate imdusiran. The filing serves as a routine update for investors regarding the company's pipeline, clinical trial designs, and future prospects.